Lab study explores cannabis compounds for inflammatory disease treatment
NCT ID NCT06842316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how natural cannabis compounds (phytocannabinoids) affect immune cells from 100 people with chronic inflammatory diseases like rheumatoid arthritis, lupus, and Crohn's disease. Researchers will take a blood sample and expose the cells to different cannabis extracts in a lab to see if they reduce inflammation. The goal is to find which cannabis profiles work best, but this is early lab research, not a treatment for patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU d'ORLEANS
RECRUITINGOrléans, 45067, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict how kids with IBD will respond to treatment?
- Can a new antibody help lupus patients ditch steroids?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- A swallowable spy pill could unlock Sjögren's secrets
- Ultrasound may uncover hidden arthritis in IBD patients